Literature DB >> 7859919

Relative quantitative analysis of glucagon receptor mRNA in rat tissues.

M Svoboda1, M Tastenoy, P Vertongen, P Robberecht.   

Abstract

Total RNA prepared from nine rat tissues were analyzed for their content in glucagon receptor mRNA by two independent hybridization approaches: (1) simple dot blot analysis using labelled oligodeoxynucleotide; (2) highly specific RNase protection assay using labelled antisense RNA. Hybridization signal was quantified by laser densitometric scanning of autoradiographies. Results were expressed for each method relative to the liver content (100%) for either a constant amount of total RNA or for a constant amount of beta-actin mRNA. We obtained similar relative values of glucagon receptor mRNA per constant amount of total RNA by the two hybridization methods: in liver (100 and 100), in kidney (38 and 34), and in heart (12 and 11). The glucagon receptor mRNA was overestimated by the less specific dot assays, in adrenal glands (21 versus 10) and in adipose tissues (24 versus 5). In the stomach, brain, duodenum and lung, the signal was equal to or below the reliable quantification limit. Reverse transcription and polymerase chain reaction (RT-PCR) of glucagon receptor mRNA with limited cycle number were performed using two sets of primers: the first set amplified a single band at the 3' coding end, and the second, 3-6 bands at the 5' coding end, revealing tissue-specific polymorphism. RT-PCR data confirmed the presence of glucagon receptor mRNA in liver, kidney, heart, adrenal glands and adipose tissue, and allowed the detection of a very low amount of glucagon receptor mRNA in the stomach, the duodenum and brain but not in the lung.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859919     DOI: 10.1016/0303-7207(94)90162-7

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  24 in total

Review 1.  Minireview: Glucagon in stress and energy homeostasis.

Authors:  B J Jones; T Tan; S R Bloom
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

2.  Dexamethasone-induced decrease in HMG-CoA reductase and protein-farnesyl transferase activities does not impair ras processing in AR 4-2J cells.

Authors:  M Lambert; N D Bui
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

Review 3.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

4.  Glucagon regulates ACC activity in adipocytes through the CAMKKβ/AMPK pathway.

Authors:  I-Chen Peng; Zhen Chen; Wei Sun; Ying-Shiuan Li; Traci LaNai Marin; Pang-Hung Hsu; Mei-I Su; Xiaopei Cui; Songqin Pan; Christian Y Lytle; David A Johnson; Frank Blaeser; Talal Chatila; John Y-J Shyy
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-27       Impact factor: 4.310

Review 5.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

6.  Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.

Authors:  Safina Ali; Benjamin J Lamont; Maureen J Charron; Daniel J Drucker
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

Review 7.  The metabolic actions of glucagon revisited.

Authors:  Kirk M Habegger; Kristy M Heppner; Nori Geary; Timothy J Bartness; Richard DiMarchi; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2010-10-19       Impact factor: 43.330

8.  Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

Authors:  A M Arafat; P Kaczmarek; M Skrzypski; E Pruszyńska-Oszmalek; P Kołodziejski; D Szczepankiewicz; M Sassek; T Wojciechowicz; B Wiedenmann; A F H Pfeiffer; K W Nowak; M Z Strowski
Journal:  Diabetologia       Date:  2012-12-22       Impact factor: 10.122

9.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

Review 10.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.